X4 Pharmaceuticals, Inc — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
X4 Pharmaceuticals appointed Kelly Gold, currently CFO of CAMP4 Therapeutics, as a Class II independent director effective July 1, 2026. Board size increased from 5 to 6 directors. Ms. Gold appointed to Audit Committee. No dollar amounts, equity grants, or compensation details disclosed in filing; company references standard non-employee director compensation per March 2026 proxy statement.
Why this rating
Routine board appointment; no material financial impact. At $14.9M market cap, standard governance action. Company at clinical stage; appointment adds biotech/finance expertise but is administrative, not business-changing.
Extracted items
- 5.02 exec change
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.